Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers - Paluch-Shimon, S; Friedman, E; Berger, R (Breast Cancer Res Treat, 2016)